Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Feraheme (Ferumoxytol) Is Recognized by Proinflammatory and Anti-inflammatory Macrophages via Scavenger Receptor Type AI/II.

Wang G, Serkova NJ, Groman EV, Scheinman RI, Simberg D.

Mol Pharm. 2019 Oct 7;16(10):4274-4281. doi: 10.1021/acs.molpharmaceut.9b00632. Epub 2019 Sep 26.

PMID:
31556296
2.

Evaluation of Targeting Efficiency of Joints with Anticollagen II Antibodies.

Lofchy LA, Vu VP, Banda NK, Ramirez JR, Smith WJ, Gifford G, Gaikwad H, Scheinman RI, Simberg D.

Mol Pharm. 2019 Jun 3;16(6):2445-2451. doi: 10.1021/acs.molpharmaceut.9b00059. Epub 2019 May 15.

PMID:
31091104
3.

Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.

Gifford G, Vu VP, Banda NK, Holers VM, Wang G, Groman EV, Backos D, Scheinman R, Moghimi SM, Simberg D.

J Control Release. 2019 May 28;302:181-189. doi: 10.1016/j.jconrel.2019.04.009. Epub 2019 Apr 8.

PMID:
30974134
4.

Publisher Correction: Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles.

Vu VP, Gifford GB, Chen F, Benasutti H, Wang G, Groman EV, Scheinman R, Saba L, Moghimi SM, Simberg D.

Nat Nanotechnol. 2019 Mar;14(3):298. doi: 10.1038/s41565-019-0379-0.

PMID:
30670872
5.

Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles.

Vu VP, Gifford GB, Chen F, Benasutti H, Wang G, Groman EV, Scheinman R, Saba L, Moghimi SM, Simberg D.

Nat Nanotechnol. 2019 Mar;14(3):260-268. doi: 10.1038/s41565-018-0344-3. Epub 2019 Jan 14. Erratum in: Nat Nanotechnol. 2019 Jan 22;:.

6.

Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis.

Banda NK, Desai D, Scheinman RI, Pihl R, Sekine H, Fujita T, Sharma V, Hansen AG, Garred P, Thiel S, Borodovsky A, Holers VM.

Immunohorizons. 2018 Sep;2(8):274-295. doi: 10.4049/immunohorizons.1800053.

7.

Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population.

Benasutti H, Wang G, Vu VP, Scheinman R, Groman E, Saba L, Simberg D.

Bioconjug Chem. 2017 Nov 15;28(11):2747-2755. doi: 10.1021/acs.bioconjchem.7b00496. Epub 2017 Nov 1.

8.

Revealing Dynamics of Accumulation of Systemically Injected Liposomes in the Skin by Intravital Microscopy.

Griffin JI, Wang G, Smith WJ, Vu VP, Scheinman R, Stitch D, Moldovan R, Moghimi SM, Simberg D.

ACS Nano. 2017 Nov 28;11(11):11584-11593. doi: 10.1021/acsnano.7b06524. Epub 2017 Oct 18.

9.

Deconstructing the Lectin Pathway in the Pathogenesis of Experimental Inflammatory Arthritis: Essential Role of the Lectin Ficolin B and Mannose-Binding Protein-Associated Serine Protease 2.

Banda NK, Acharya S, Scheinman RI, Mehta G, Takahashi M, Endo Y, Zhou W, Farrar CA, Sacks SH, Fujita T, Sekine H, Holers VM.

J Immunol. 2017 Sep 1;199(5):1835-1845. doi: 10.4049/jimmunol.1700119. Epub 2017 Jul 24.

10.

Mannan-Binding Lectin-Associated Serine Protease 1/3 Cleavage of Pro-Factor D into Factor D In Vivo and Attenuation of Collagen Antibody-Induced Arthritis through Their Targeted Inhibition by RNA Interference-Mediated Gene Silencing.

Banda NK, Acharya S, Scheinman RI, Mehta G, Coulombe M, Takahashi M, Sekine H, Thiel S, Fujita T, Holers VM.

J Immunol. 2016 Nov 1;197(9):3680-3694. Epub 2016 Oct 5.

11.

A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.

Mehta G, Scheinman RI, Holers VM, Banda NK.

J Immunol. 2015 Jun 1;194(11):5446-54. doi: 10.4049/jimmunol.1403012. Epub 2015 Apr 27.

12.
13.

Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier.

Kadam RS, Scheinman RI, Kompella UB.

Mol Pharm. 2012 Nov 5;9(11):3228-35. doi: 10.1021/mp300305f. Epub 2012 Oct 15.

14.

Pleiotropic targets: the problem of shared signaling circuitry in rheumatoid arthritis disease progression and protection.

Scheinman RI.

Future Med Chem. 2012 Apr;4(6):735-50. doi: 10.4155/fmc.12.27. Review.

PMID:
22530638
15.

Rheumatology mini focus.

Scheinman RI.

Future Med Chem. 2012 Apr;4(6):697-9. doi: 10.4155/fmc.12.33. No abstract available.

16.

Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model.

Scheinman RI, Trivedi R, Vermillion S, Kompella UB.

Nanomedicine (Lond). 2011 Dec;6(10):1669-82. doi: 10.2217/nnm.11.90. Epub 2011 Nov 17.

PMID:
22087799
17.

Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage.

Thakur A, Scheinman RI, Rao VR, Kompella UB.

Microvasc Res. 2011 Nov;82(3):346-50. doi: 10.1016/j.mvr.2011.09.001. Epub 2011 Sep 16.

18.

LEDGF(1-326) decreases P23H and wild type rhodopsin aggregates and P23H rhodopsin mediated cell damage in human retinal pigment epithelial cells.

Baid R, Scheinman RI, Shinohara T, Singh DP, Kompella UB.

PLoS One. 2011;6(9):e24616. doi: 10.1371/journal.pone.0024616. Epub 2011 Sep 7.

19.

Mycobacterium tuberculosis increases IP-10 and MIG protein despite inhibition of IP-10 and MIG transcription.

Bai X, Chmura K, Ovrutsky AR, Bowler RP, Scheinman RI, Oberley-Deegan RE, Liu H, Shang S, Ordway D, Chan ED.

Tuberculosis (Edinb). 2011 Jan;91(1):26-35. doi: 10.1016/j.tube.2010.11.005. Epub 2010 Dec 16.

PMID:
21167783
20.

Spine and pain clinics serving North Carolina patients with back and neck pain: what do they do, and are they multidisciplinary?

Castel LD, Freburger JK, Holmes GM, Scheinman RP, Jackman AM, Carey TS.

Spine (Phila Pa 1976). 2009 Mar 15;34(6):615-22. doi: 10.1097/BRS.0b013e31817b8fa2.

21.

Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis.

Weiser-Evans MC, Wang XQ, Amin J, Van Putten V, Choudhary R, Winn RA, Scheinman R, Simpson P, Geraci MW, Nemenoff RA.

Cancer Res. 2009 Mar 1;69(5):1733-8. doi: 10.1158/0008-5472.CAN-08-3766. Epub 2009 Feb 10.

22.

Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model.

Williams-Skipp C, Raman T, Valuck RJ, Watkins H, Palmer BE, Scheinman RI.

Arthritis Rheum. 2009 Feb;60(2):408-18. doi: 10.1002/art.24260.

23.

Sodium butyrate alters erythropoietin glycosylation via multiple mechanisms.

Crowell CK, Qin Q, Grampp GE, Radcliffe RA, Rogers GN, Scheinman RI.

Biotechnol Bioeng. 2008 Jan 1;99(1):201-13.

PMID:
17570711
24.

Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system.

Crowell CK, Grampp GE, Rogers GN, Miller J, Scheinman RI.

Biotechnol Bioeng. 2007 Feb 15;96(3):538-49.

PMID:
16937399
25.

Loss of a gimap/ian gene leads to activation of NF-kappaB through a MAPK-dependent pathway.

Kupfer R, Lang J, Williams-Skipp C, Nelson M, Bellgrau D, Scheinman RI.

Mol Immunol. 2007 Jan;44(4):479-87. Epub 2006 Apr 11.

PMID:
16584774
26.

AIRE recruits multiple transcriptional components to specific genomic regions through tethering to nuclear matrix.

Tao Y, Kupfer R, Stewart BJ, Williams-Skipp C, Crowell CK, Patel DD, Sain S, Scheinman RI.

Mol Immunol. 2006 Feb;43(4):335-45. Epub 2005 Mar 23.

PMID:
16310047
27.

Partial activation precedes apoptotic death in T cells harboring an IAN gene mutation.

Lang JA, Kominski D, Bellgrau D, Scheinman RI.

Eur J Immunol. 2004 Sep;34(9):2396-406.

28.

Increased NF-kappa B activity in B cells and bone marrow-derived dendritic cells from NOD mice.

Wheat W, Kupfer R, Gutches DG, Rayat GR, Beilke J, Scheinman RI, Wegmann DR.

Eur J Immunol. 2004 May;34(5):1395-404.

29.

Measurement of IKK activity in primary rat T cells: rapid activation and inactivation.

Kupfer R, Scheinman RI.

J Immunol Methods. 2002 Aug 1;266(1-2):155-64.

PMID:
12133632
30.

4-hydroxynonenal decreases interleukin-6 expression and protein production in primary rat Kupffer cells by inhibiting nuclear factor-kappaB activation.

Luckey SW, Taylor M, Sampey BP, Scheinman RI, Petersen DR.

J Pharmacol Exp Ther. 2002 Jul;302(1):296-303.

PMID:
12065730
31.

The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism.

Cota-Gomez A, Flores NC, Cruz C, Casullo A, Aw TY, Ichikawa H, Schaack J, Scheinman R, Flores SC.

J Biol Chem. 2002 Apr 26;277(17):14390-9. Epub 2002 Feb 4.

32.

TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells.

Spalding AC, Jotte RM, Scheinman RI, Geraci MW, Clarke P, Tyler KL, Johnson GL.

Oncogene. 2002 Jan 10;21(2):260-71.

33.

NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).

Pawlowski JE, Nesterov A, Scheinman RI, Johnson TR, Kraft AS.

Anticancer Res. 2000 Nov-Dec;20(6B):4243-55.

PMID:
11205254
34.

The identification of a novel T cell activation state controlled by a diabetogenic gene.

Moore JK, Scheinman RI, Bellgrau D.

J Immunol. 2001 Jan 1;166(1):241-8.

35.

Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis.

Tao Y, Williams-Skipp C, Scheinman RI.

J Biol Chem. 2001 Jan 26;276(4):2329-32. Epub 2000 Dec 5.

36.

NF-kappaB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type.

Lin B, Williams-Skipp C, Tao Y, Schleicher MS, Cano LL, Duke RC, Scheinman RI.

Cell Death Differ. 1999 Jun;6(6):570-82.

37.

Molecular mechanism of basic calcium phosphate crystal-induced activation of human fibroblasts. Role of nuclear factor kappab, activator protein 1, and protein kinase c.

McCarthy GM, Augustine JA, Baldwin AS, Christopherson PA, Cheung HS, Westfall PR, Scheinman RI.

J Biol Chem. 1998 Dec 25;273(52):35161-9.

38.

Contextual dependence of steroid receptor function on an androgen-responsive enhancer.

Scheller A, Scheinman RI, Thompson E, Scarlett CO, Robins DM.

Mol Cell Endocrinol. 1996 Jul 23;121(1):75-86.

PMID:
8865168
39.

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids.

Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr.

Science. 1995 Oct 13;270(5234):283-6.

PMID:
7569975
40.
41.

Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors.

Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr.

Mol Cell Biol. 1995 Feb;15(2):943-53.

42.

NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule.

Scheinman RI, Beg AA, Baldwin AS Jr.

Mol Cell Biol. 1993 Oct;13(10):6089-101.

43.

Promoter of the human NF-kappa B p50/p105 gene. Regulation by NF-kappa B subunits and by c-REL.

Cogswell PC, Scheinman RI, Baldwin AS Jr.

J Immunol. 1993 Apr 1;150(7):2794-804.

PMID:
8454856
44.

I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention.

Beg AA, Ruben SM, Scheinman RI, Haskill S, Rosen CA, Baldwin AS Jr.

Genes Dev. 1992 Oct;6(10):1899-913. Erratum in: Genes Dev 1992 Dec;6(12B):2664-5.

45.

Developmental regulation of sodium channel expression in the rat forebrain.

Scheinman RI, Auld VJ, Goldin AL, Davidson N, Dunn RJ, Catterall WA.

J Biol Chem. 1989 Jun 25;264(18):10660-6.

46.

Sodium channel expression and assembly during development of retinal ganglion cells.

Wollner DA, Scheinman R, Catterall WA.

Neuron. 1988 Oct;1(8):727-37.

PMID:
2856102
47.

Random-clone strategy for genomic restriction mapping in yeast.

Olson MV, Dutchik JE, Graham MY, Brodeur GM, Helms C, Frank M, MacCollin M, Scheinman R, Frank T.

Proc Natl Acad Sci U S A. 1986 Oct;83(20):7826-30.

49.

Kinetics of proliferation of splenic macrophage precursor cells during the early primary immune response.

Pluznik DH, Rotter V, Scheinman R.

J Reticuloendothel Soc. 1972 Feb;11(2):154-66. No abstract available.

PMID:
4555127

Supplemental Content

Loading ...
Support Center